PortalPublikationenFour-year allograft survival in a highly sensitized combined...

Four-year allograft survival in a highly sensitized combined liver-kidney transplant patient despite unsuccessful anti-HLA antibody reduction with rituximab, splenectomy, and bortezomib.

Standard

Four-year allograft survival in a highly sensitized combined liver-kidney transplant patient despite unsuccessful anti-HLA antibody reduction with rituximab, splenectomy, and bortezomib. / Koch, Martina; Graeser, Christian; Lehnhardt, Anja; Pollok, Joerg-Matthias; Kröger, Nicolaus-Martin; Verboom, Murielle; Thaiss, Friedrich; Eiermann, Thomas; Nashan, Björn.

in: TRANSPL INT, Jahrgang 26, Nr. 8, 8, 2013, S. 64-68.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Koch, M, Graeser, C, Lehnhardt, A, Pollok, J-M, Kröger, N-M, Verboom, M, Thaiss, F, Eiermann, T & Nashan, B 2013, 'Four-year allograft survival in a highly sensitized combined liver-kidney transplant patient despite unsuccessful anti-HLA antibody reduction with rituximab, splenectomy, and bortezomib.', TRANSPL INT, Jg. 26, Nr. 8, 8, S. 64-68. https://doi.org/10.1111/tri.12120

APA

Koch, M., Graeser, C., Lehnhardt, A., Pollok, J-M., Kröger, N-M., Verboom, M., Thaiss, F., Eiermann, T., & Nashan, B. (2013). Four-year allograft survival in a highly sensitized combined liver-kidney transplant patient despite unsuccessful anti-HLA antibody reduction with rituximab, splenectomy, and bortezomib. TRANSPL INT, 26(8), 64-68. [8]. https://doi.org/10.1111/tri.12120

Vancouver

Koch M, Graeser C, Lehnhardt A, Pollok J-M, Kröger N-M, Verboom M et al. Four-year allograft survival in a highly sensitized combined liver-kidney transplant patient despite unsuccessful anti-HLA antibody reduction with rituximab, splenectomy, and bortezomib. TRANSPL INT. 2013;26(8):64-68. 8. https://doi.org/10.1111/tri.12120

Bibtex

@article{f5ed35eed69e4151a314681dd4ccde94,
title = "Four-year allograft survival in a highly sensitized combined liver-kidney transplant patient despite unsuccessful anti-HLA antibody reduction with rituximab, splenectomy, and bortezomib.",
abstract = "Although donor-specific lymphocytotoxic antibodies are regarded as a contraindication for kidney transplantation (KTx), the data available for liver or combined liver or kidney transplantation (cLKTx) are scarce. Here, we report a case of a highly sensitized young man receiving his sixth liver and second kidney graft. Multiple anti-HLA antibodies were present at the time of transplantation. As a result of suspected antibody-mediated graft damage, the patient was treated with rituximab, plasmapheresis, intravenous immunoglobulins, splenectomy, and bortezomib to decrease the antibody production. So far, patient and allograft survival has reached 4 years despite failure to achieve a permanent reduction of anti-HLA antibodies, and particularly nondonor directed antibodies.",
keywords = "Adult, Antibodies, Monoclonal, Murine-Derived, Boronic Acids, Graft Rejection, Graft Survival, HLA Antigens, Humans, Immunoglobulins, Intravenous, Kidney Transplantation, Liver Transplantation, Male, Plasmapheresis, Pyrazines, Splenectomy",
author = "Martina Koch and Christian Graeser and Anja Lehnhardt and Joerg-Matthias Pollok and Nicolaus-Martin Kr{\"o}ger and Murielle Verboom and Friedrich Thaiss and Thomas Eiermann and Bj{\"o}rn Nashan",
note = "{\textcopyright} 2013 Steunstichting ESOT. Published by John Wiley & Sons Ltd.",
year = "2013",
doi = "10.1111/tri.12120",
language = "English",
volume = "26",
pages = "64--68",
journal = "TRANSPL INT",
issn = "0934-0874",
publisher = "Wiley-Blackwell",
number = "8",

}

RIS

TY - JOUR

T1 - Four-year allograft survival in a highly sensitized combined liver-kidney transplant patient despite unsuccessful anti-HLA antibody reduction with rituximab, splenectomy, and bortezomib.

AU - Koch, Martina

AU - Graeser, Christian

AU - Lehnhardt, Anja

AU - Pollok, Joerg-Matthias

AU - Kröger, Nicolaus-Martin

AU - Verboom, Murielle

AU - Thaiss, Friedrich

AU - Eiermann, Thomas

AU - Nashan, Björn

N1 - © 2013 Steunstichting ESOT. Published by John Wiley & Sons Ltd.

PY - 2013

Y1 - 2013

N2 - Although donor-specific lymphocytotoxic antibodies are regarded as a contraindication for kidney transplantation (KTx), the data available for liver or combined liver or kidney transplantation (cLKTx) are scarce. Here, we report a case of a highly sensitized young man receiving his sixth liver and second kidney graft. Multiple anti-HLA antibodies were present at the time of transplantation. As a result of suspected antibody-mediated graft damage, the patient was treated with rituximab, plasmapheresis, intravenous immunoglobulins, splenectomy, and bortezomib to decrease the antibody production. So far, patient and allograft survival has reached 4 years despite failure to achieve a permanent reduction of anti-HLA antibodies, and particularly nondonor directed antibodies.

AB - Although donor-specific lymphocytotoxic antibodies are regarded as a contraindication for kidney transplantation (KTx), the data available for liver or combined liver or kidney transplantation (cLKTx) are scarce. Here, we report a case of a highly sensitized young man receiving his sixth liver and second kidney graft. Multiple anti-HLA antibodies were present at the time of transplantation. As a result of suspected antibody-mediated graft damage, the patient was treated with rituximab, plasmapheresis, intravenous immunoglobulins, splenectomy, and bortezomib to decrease the antibody production. So far, patient and allograft survival has reached 4 years despite failure to achieve a permanent reduction of anti-HLA antibodies, and particularly nondonor directed antibodies.

KW - Adult

KW - Antibodies, Monoclonal, Murine-Derived

KW - Boronic Acids

KW - Graft Rejection

KW - Graft Survival

KW - HLA Antigens

KW - Humans

KW - Immunoglobulins, Intravenous

KW - Kidney Transplantation

KW - Liver Transplantation

KW - Male

KW - Plasmapheresis

KW - Pyrazines

KW - Splenectomy

U2 - 10.1111/tri.12120

DO - 10.1111/tri.12120

M3 - SCORING: Journal article

C2 - 23672514

VL - 26

SP - 64

EP - 68

JO - TRANSPL INT

JF - TRANSPL INT

SN - 0934-0874

IS - 8

M1 - 8

ER -